{"id":57984,"date":"2026-02-26T13:01:50","date_gmt":"2026-02-26T05:01:50","guid":{"rendered":"https:\/\/flcube.com\/?p=57984"},"modified":"2026-02-26T13:01:51","modified_gmt":"2026-02-26T05:01:51","slug":"gsk-to-acquire-35pharma-for-950m-adds-potential-best-in-class-pah-asset-hs235","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=57984","title":{"rendered":"GSK to Acquire 35Pharma for $950M \u2013 Adds Potential Best\u2011in\u2011Class PAH Asset HS235"},"content":{"rendered":"\n

GlaxoSmithKline (GSK, NYSE:\u202fGSK<\/a>)<\/strong> announced a definitive agreement to acquire 35Pharma Inc.<\/strong>, a Canada\u2011based clinical\u2011stage biopharmaceutical company<\/strong> specializing in novel protein\u2011based therapeutics<\/strong>, for USD\u202f950\u202fmillion in cash<\/strong>. The acquisition provides GSK with HS235<\/strong>, a potential best\u2011in\u2011class investigational medicine<\/strong> targeting pulmonary arterial hypertension (PAH)<\/strong> and pulmonary hypertension due to heart failure with preserved ejection fraction (PH\u2011HFpEF)<\/strong>, along with broad metabolic applications.<\/p>\n\n\n\n

Transaction Overview<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Acquirer<\/strong><\/td>GlaxoSmithKline (GSK, NYSE:\u202fGSK)<\/td><\/tr>
Target<\/strong><\/td>35Pharma Inc. (Canada\u2011based, private, clinical\u2011stage)<\/td><\/tr>
Transaction Value<\/strong><\/td>USD\u202f950\u202fmillion<\/strong> (cash at closing)<\/td><\/tr>
Equity Acquired<\/strong><\/td>100%<\/td><\/tr>
Core Asset<\/strong><\/td>HS235 (protein\u2011based therapeutic)<\/td><\/tr>
Target Specialization<\/strong><\/td>Novel protein\u2011based therapeutics<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Lead Asset \u2013 HS235<\/h2>\n\n\n\n
Parameter<\/th>Detail<\/th><\/tr><\/thead>
Class<\/strong><\/td>Protein\u2011based therapeutic<\/td><\/tr>
Target Pathway<\/strong><\/td>Activin receptor signaling pathway<\/strong> \u2013 clinically validated in PH<\/td><\/tr>
Indications<\/strong><\/td>Pulmonary arterial hypertension (PAH); PH due to HFpEF<\/td><\/tr>
Clinical Status<\/strong><\/td>Phase I completed (healthy volunteers); Phase II initiation imminent<\/td><\/tr>
Differentiation<\/strong><\/td>Potential best\u2011in\u2011class<\/strong> profile<\/td><\/tr>
Key Advantage<\/strong><\/td>Lower bleeding risk vs. current PH therapies<\/td><\/tr>
Metabolic Benefits<\/strong><\/td>Fat\u2011selective weight loss; lean mass preservation; improved insulin sensitivity<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Disease Context \u2013 Pulmonary Hypertension<\/h2>\n\n\n\n
Feature<\/th>Detail<\/th><\/tr><\/thead>
Disease Nature<\/strong><\/td>Progressive, life\u2011shortening condition<\/td><\/tr>
Pathophysiology<\/strong><\/td>High blood pressure in pulmonary arteries<\/td><\/tr>
Current Limitations<\/strong><\/td>Existing therapies carry bleeding risk; limited efficacy in PH\u2011HFpEF<\/td><\/tr>
Unmet Need<\/strong><\/td>Safer, more effective treatments with metabolic co\u2011benefits<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Strategic Rationale<\/h2>\n\n\n\n